#\Genomics Market Analysis

[industrynewsupdates]

Genomics Market Business Growth, Opportunities and Forecast 2024-2030

The global genomics market size was valued at USD 32.65 billion in 2023 and is projected to witness a compound annual growth rate (CAGR) of 16.5% from 2024 to 2030. 

The growth of genomics market is attributed to factors such as growing demand for gene therapy, personalized medicine, drug discovery, increasing cancer incidence, and a significant increase in demand for consumer genomics in recent years. Moreover, increasing number of joint ventures and partnerships amongst market players is also expected to have a positive impact on the genomics market growth. For instance, in June 2022, Illumina, Inc., and Allegheny Health Network signed a collaboration for effective evaluation of the impact of in-house Comprehensive Genomic Profiling (CGP) to leverage patient care.

Gather more insights about the market drivers, restrains and growth of the Genomics Market 

The COVID-19 pandemic outbreak had posed challenges to applications of genomics technology in terms of research and therapeutics. Nevertheless, some niche applications were of great use to mankind during the pandemic situation to facilitate immediate attention for designing effective diagnostics, effective therapeutics and steps to curb the spread of COVID-19.  For example, the viral genome mutational rate (~1-2 bases per month) was gauged for validity of PCR cycle was estimated to understand the efficacy of the re-purposed anti-viral treatments and thereby the vaccine development process was streamlined.

Many genomic surveillance programs were launched country wise to understand the dynamics of pandemic situation and to effective preventive measures. For instance, in December 2020, the Indian SARS-CoV-2 Genomics Consortium (INSACOG) was launched by the joint efforts of Department of Biotechnology (DBT), Ministry of Health, and ICMR with an aim to screen the genomic variations in the SARS-CoV-2 by sequencing technologies. Furthermore, country specific companies are providing consumer genomics services which is also expected to fuel the market size in coming years. One such company being Mapmygenome which is one of the pioneers in India offers DTC genomics services.

The increasing prevalence of inherited cancers is expected create a high demand for cancer genomics. The substantial understanding of human genome have targeted focus on use of various gene therapies for treatment of cancers by modern gene editing techniques such as CRISPR-Cas gene technology. For instance, in September 2022, a group of researchers at the University of California introduced the applications of precision genome editing agents for management of inherited retinal diseases (IRDs).

The development of high-throughput sequencing technologies such as Next-Generation Sequencing (NGS) and microarrays has generated massive amounts of genomic data. However, the rapid accumulation of this data from DNA sequencing and Electronic Health Records (EHRs) poses significant challenges and opportunities for the extraction of biologically or clinically relevant information. Phenome-wide association study (PheWAS) & genome-wide association study (GWAS) are helping researchers to study correlations between genotype and phenotype.

The market players are extensively working towards collaborations, expansions, acquisitions and huge capital investments to advance in research to understand rare diseases and to aid drug discovery. For instance, PacBio declares a collaboration with the Genomics England society for the utility of PacBio’s technology to detect genetic variation in unexplained rare disorders. The study is intended to re-sequence a selection of samples collected during Genomics England’s 100,000 genomes project to discover potential operational and clinical benefits of long-read sequencing for the identification of mutations associated with rare diseases.

Genomics Market Segmentation

Grand View Research has segmented the global genomics market based on application, technology, deliverables, end-use, and region:

Application & Technology Outlook (Revenue, USD Billion, 2018 - 2030)

• Functional Genomics

• Transfection

• Real-Time PCR

• RNA Interference

• Mutational Analysis

• SNP Analysis

• Microarray Analysis

• Epigenomics

• Bisulfite Sequencing

• Chromatin Immunoprecipitation (ChIP & ChIP-Seq)

• Methylated DNA Immunoprecipitation (MeDIP)

• High-Resolution Melt (HRM)

• Chromatin Accessibility Assays

• Microarray Analysis

• Pathway Analysis

• Bead-Based Analysis

• Microarray Analysis

• Real-time PCR

• Proteomics Tools (2-D PAGE; yeast 2-hybrid studies)

• Biomarker Discovery

• Mass Spectrometry

• Real-time PCR

• Microarray Analysis

• Statistical Analysis

• Bioinformatics

• DNA Sequencing

• Others

Technology Outlook (Revenue, USD Billion, 2018 - 2030)

• Sequencing

• PCR

• Flow Cytometry

• Microarrays

• Other technologies

Deliverables Outlook (Revenue, USD Billion, 2018 - 2030)

• Products

o Instruments/Systems/Software

o Consumables & Reagents

• Services

o NGS-based Services

o Core Genomics Services

o Biomarker Translation Services

o Computational Services

o Others

End-use Outlook (Revenue, USD Billion, 2018 - 2030)

• Clinical Research

• Academic & Government Institutes

• Hospitals & Clinics

• Pharmaceutical & Biotechnology Companies

• Other End Users

Regional Outlook (Revenue, USD Billion, 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o Germany

o U.K.

o France

o Italy

o Spain

o Denmark

o Sweden

o Norway

• Asia Pacific

o China

o India

o Japan

o South Korea

o Australia

o Thailand

• Latin America

o Brazil

o Mexico

o Argentina

• Middle East & Africa

o South Africa

o Saudi Arabia

o UAE

o Kuwait

Browse through Grand View Research's Biotechnology Industry Research Reports.

• The global cell sorting market size was valued at USD 242.7 million in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 8.6% from 2024 to 2030. 

• The global live cell imaging market size was valued at USD 2.48 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 9.0% from 2024 to 2030.

Key Companies & Market Share Insights

The market players operating in the genomics market are adopting product approval to increase the reach of their products in the market and improve the availability of their products & services in diverse geographical areas, along with expansion as a strategy to enhance production/research activities. In addition, several market players are acquiring smaller players to strengthen their market position. This strategy enables companies to increase their capabilities, expand their product portfolios, and improve their competencies.

Key Genomics Companies:

• Agilent Technologies

• Bio-Rad Laboratories, Inc.

• BGI Genomics

• Color Genomics, Inc.

• Danaher Corporation

• Eppendorf AG

• Eurofins Scientific

• F. Hoffmann-La Roche Ltd.

• GE Healthcare

• Illumina, Inc.

• Myriad Genetics, Inc.

• Oxford Nanopore Technologies

• Pacific Biosciences of California, Inc.

• QIAGEN N.V.

• Quest Diagnostics Incorporated

• Thermo Fisher Scientific, Inc.

• 23andMe, Inc.

Recent Development

• In November 2023, Fabric Genomics collaborated with DNAnexus and Oxford Nanopore Technologies for deployment of CLIA/CAP labs in pediatric and neonatal ICU’s. The labs will use Oxford Nanopore’s platforms to study genetic disorders in infants.

• In February 2023, Illumina, Inc. entered into a collaboration with African Centre of Excellence for Genomics of Infectious Diseases to start a training institute to increase genomic capabilities in African region

• In January 2023, SOPHiA GENETIC collaborated with the Memorial Sloan Kettering Cancer Center (MSK), a U.S. Cancer Center, to offer researchers and clinicians solutions to expand analytical and testing capabilities.

• In January 2023, Agilent Technologies, Inc. announced acquisition of Avida Biomed, a company that develops target enrichment workflows for clinical researchers utilizing NGS methods to study cancers.

• In April 2022, QIAGEN launched the Biomedical Knowledge Base in Europe, Japan, North America, and Australia to support data science applications in biotech companies 

Order a free sample PDF of the Genomics Market Intelligence Study, published by Grand View Research.

[trendingreportz]

Single-cell Genome Sequencing Market - Forecast(2024 - 2030)

Single-cell Genome Sequencing Market Overview 

The Single-cell Genome Sequencing size is estimated to reach $9 billion by 2030, growing at a CAGR of 16.2% during the forecast period 2023-2030. Single-cell genome sequencing is one of the major areas of research for finding a cure for chronic ailments such as cancer. The rising cases of cancer worldwide would drive the Single-cell Genome Sequencing Market during the forecast period. According to Cancer.org, the global burden of new cancer cases would grow to 27.5 million by 2040. This would certainly boost the demand for Single-cell Genome Sequencing Market to find a cure for such chronic diseases.

Rapid development in sequencing technologies is also expected to drive the growth of this market during the forecast period. Polymerase chain reaction (PCR) and next-generation sequencing are emerging as the preferred technologies for various applications, especially for single-cell genomic sequencing. In January 2022, a group of medical Scientists at Stanford and their collaborators developed a new ultra-fast genome sequencing approach that offered a diagnostic rate of about 12% higher than the average rate for diagnosing mystery illnesses.

Request Sample

Single-cell Genome Sequencing Market - Report Coverage:

The “Single-cell Genome Sequencing Market Report- Forecast (2023-2030)” by IndustryARC, covers an in-depth analysis of the following segments in the Single-cell Genome Sequencing Market.AttributeSegment

By Product Type

Consumables

Reagents

By Technique

Flow Cytometry

Next-generation Sequencing

Polymerase Chain Reaction

Microscopy

Mass Spectrometry

Others

By Application

Cancer

Immunology

Microbiology

Others

By End-User

Academic and Research Laboratories

Hospitals and Diagnostic Centers

Biotechnology and Pharmaceutical Companies

Cell Banks and IVF Centers

By Geography

North America (the U.S., Canada and Mexico)

Europe (Germany, France, the UK, Italy, Spain, Russia and the Rest of Europe),

Asia-Pacific (China, Japan, South Korea, India, Australia & New Zealand and the Rest of Asia-Pacific),

South America (Brazil, Argentina, Chile, Colombia and the Rest of South America)

The Rest of the World (the Middle East and Africa).

COVID-19 / Ukraine Crisis - Impact Analysis: 

The COVID-19 pandemic had a positive impact on the Single-cell Genome Sequencing Market. The studies on single-cell genome sequencing offered critical insights into coronavirus infection and allowed medical experts better understand the nature of the infection. On performing single-cell sequencing, most cell types in patients with COVID-19 showed a significant interferon-α response along with an overall acute inflammatory response.

 Russia’s invasion of Ukraine has made a significant impact on the Single-cell Genome Sequencing market. It has not only affected the lives and work of genomic researchers in these countries but has also influenced the relationships with colleagues in the U.S. and elsewhere.

The sanctions against Russia are most likely to bring experimental genomics research in the country to a halt. Ukraine had several genomics research projects going on before the war began. Now, with all the unrest, most researchers in Ukraine are fleeing the country and looking for positions in the west.

Inquiry Before Buying

Key Takeaways: 

Fastest Growth in the Asia-Pacific Region : Geographically, in the global Single-cell Genome Sequencing market share, Asia-Pacific is analyzed to grow with the highest CAGR of 17.2% during the forecast period 2023-2030. This growth is driven by the rising number of cancer cases in the region. According to the projections by the International Agency for Research on Cancer, there would be about 15.1 million new cases per year in Asia until 2040. The unprecedented rate of population aging is the key determinant of this development. Japan, the country with the oldest population in the world, also has the highest rate of cancer. This would drive growth in the Single-cell Genome Sequencing Market in the region during the forecast period.

Reagents Segment to Register the Fastest Growth : In the Single-cell Genome Sequencing analysis, the Reagents segment is estimated to grow with the highest CAGR of 17% during the forecast period. This is because the use of single-cell sequencing reagents allows the experts to process bulk samples with the input of as few as 100 cells. With the recent advancements in single-cell DNA sequencing techniques, bulk DNA sequencing can be done more efficiently and cost-effectively. Moreover, commercial reagents are now available for all the wet-lab steps of a scRNA-seq protocol as well as for preparing barcoded cDNA libraries. The increasing availability of reagents and their growing need in various single-cell genome sequencing processes are boosting its growth in the Single-cell Genome Sequencing Market during the forecast period.

Academic and Research Laboratories Segment is Leading the Market : According to the Single-Cell Genome Sequencing Market forecast, the academic and research laboratories segment held the largest market share of 38.6% in 2022. Single-cell genomics is emerging as one of the major areas in scientific research and development. The rising prevalence of chronic diseases demands new cures and treatment options, which is further boosting the growth of the academic and research laboratories segment. Moreover, understanding the genomics of individual cells opens up a new set of opportunities for the world of biotechnology.

Increased Funding for Vaccine Development and Production : Government agencies in various parts of the world have increased funding for the development and production of vaccines in response to the pandemic. This has led to increased use of single-cell analysis (SCA) tools for COVID-19 research. SCA helps in the assessment of the peripheral immune function of the disease and contributes to the study of the pathophysiology and treatment possibilities of the disease. Thus, the market is positively impacted by COVID-19.

Massive Demand in the field of Immunology, Oncology and Others : Single-cell technology is used in the molecular-level examination of processes and pathways of cellular heterogeneity along with its assessment. This rapidly developing technology has major applications in immunology, oncology and other major areas. Moreover, the development of advanced tools that help make proteomic and transcriptomic processes simpler is also driving the use of single-cell analysis methods, boosting the growth of the Single-cell Genome Sequencing Market.

High Cost of Instruments to Hinder Market Growth : While there is a significant demand for genome sequencing machines among the end-user industries, the instrument costs are significantly high. According to a report published in Bloomberg, Illumina’s new NovaSeq X series costs $985,000 for the base machine and $1.25 million for the advanced one. Such high cost of instruments are likely to hinder the growth of the Single-cell Genome Sequencing Market.

Schedule a Call

Key Market Players:

Product/Service launches, approvals, patents and events, acquisitions, partnerships and collaborations are key strategies adopted by players in the Single-Cell Genome Sequencing Market.

The top 10 companies in this industry are listed below:

Standard BioTools Inc. (Maxpar®, Advanta™ Assays)

QIAGEN N.V. (QIAseq FX, REPLI-g)

Illumina, Inc. (NovaSeq, NextSeq)

F. Hoffmann-La Roche AG (AVENIO, MagNA Pure)

Thermo Fisher Scientific, Inc. (Invitrogen, Applied Biosystems)

Bio-Rad Laboratories, Inc. (SEQuoia, ddSEQ)

10X Genomics, Inc. (Chromium, Visium)

Becton, Dickinson and Company (BD Rhapsody™, BD AbSeq)

Oxford Nanopore Technologies Limited (MinION, GridION)

Beijing Genomics Institute Group (CardioGen, COLOTECT™)

 Buy Now

Scope of the Report:

Report MetricDetails

Base Year Considered

2022

Forecast Period

2023–2030

CAGR

16.2%

Market Size in 2030

$9 billion

Segments Covered

Product Type, Technique, Application, End-user and Region

Geographies Covered

North America (the U.S., Canada and Mexico) Europe (Germany, France, the UK, Italy, Spain, Russia and the Rest of Europe),Asia-Pacific (China, Japan, South Korea, India, Australia, New Zealand and the Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia and Rest of South America) and the Rest of the World (the Middle East and Africa).

Key Market Players

Standard BioTools Inc.

QIAGEN N.V.

Illumina, Inc.

F. Hoffmann-La Roche AG

Thermo Fisher Scientific, Inc.

Bio-Rad Laboratories, Inc.

10X Genomics, Inc.

Becton, Dickinson and Company

Oxford Nanopore Technologies Limited

Beijing Genomics Institute Group

Pacific Biosciences of California, Inc.

NuGEN Technologies, Inc.

Novogene Co. Ltd.

Takara Bio, Inc.

Danaher Corporation

[trendtrackershq]

𝑬𝒎𝒆𝒓𝒈𝒊𝒏𝒈 𝑻𝒓𝒆𝒏𝒅𝒔 𝒊𝒏 𝒕𝒉𝒆 𝑴𝒆𝒕𝒂𝒈𝒆𝒏𝒐𝒎𝒊𝒄𝒔 𝑴𝒂𝒓𝒌𝒆𝒕

𝑺𝒆𝒄𝒖𝒓𝒆 𝑭𝑹𝑬𝑬 𝑺𝒂𝒎𝒑𝒍𝒆: https://www.nextmsc.com/metagenomics-market/request-sample

The 𝑴𝒆𝒕𝒂𝒈𝒆𝒏𝒐𝒎𝒊𝒄𝒔 𝑴𝒂𝒓𝒌𝒆𝒕 is rapidly expanding, driven by advancements in DNA sequencing technologies and a growing focus on understanding microbial communities.

𝑲𝒆𝒚 𝑻𝒓𝒆𝒏𝒅𝒔:

𝑻𝒆𝒄𝒉𝒏𝒐𝒍𝒐𝒈𝒊𝒄𝒂𝒍 𝑨𝒅𝒗𝒂𝒏𝒄𝒆𝒎𝒆𝒏𝒕𝒔: Innovations in sequencing technologies and bioinformatics tools are enhancing the accuracy and efficiency of metagenomic studies.

𝑨𝒑𝒑𝒍𝒊𝒄𝒂𝒕𝒊𝒐𝒏𝒔 𝑨𝒄𝒓𝒐𝒔𝒔 𝑰𝒏𝒅𝒖𝒔𝒕𝒓𝒊𝒆𝒔: From healthcare to agriculture, metagenomics is revolutionizing how we approach disease detection, soil health, and more.

𝑰𝒏𝒄𝒓𝒆𝒂𝒔𝒆𝒅 𝑰𝒏𝒗𝒆𝒔𝒕𝒎𝒆𝒏𝒕: Venture capital and funding are flowing into research and development, fueling the growth of this dynamic market.

𝑾𝒉𝒚 𝑰𝒕 𝑴𝒂𝒕𝒕𝒆𝒓𝒔: Metagenomics offers insights into the microbial world that were previously unattainable, enabling breakthroughs in diagnostics, treatment strategies, and environmental management.

𝑲𝒆𝒚 𝑷𝒍𝒂𝒚𝒆𝒓𝒔: Some of the major players in the market are Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd., Enterome SA, Illumina, Inc., Pacific Biosciences of California, Inc., Oxford Nanopore Technologies Ltd., PerkinElmer, Inc., Swift Biosciences, Inc., Qiagen N.V., Thermo Fisher Scientific, Inc., and many more.

𝑨𝒄𝒄𝒆𝒔𝒔 𝑭𝒖𝒍𝒍 𝑹𝒆𝒑𝒐𝒓𝒕: https://www.nextmsc.com/report/metagenomics-market

As we look ahead, the metagenomics market promises to unlock new possibilities and drive innovation across various sectors. Stay tuned for more updates and insights into this exciting field!

[lalsingh228-blog]

Artificial Intelligence In Genomics Market May Set New Epic Growth Story

The global Artificial Intelligence In Genomics market focuses on encompassing major statistical evidence for the Artificial Intelligence In Genomics industry as it offers our readers a value addition on guiding them in encountering the obstacles surrounding the market. A comprehensive addition of several factors such as global distribution, manufacturers, market size, and market factors that affect the global contributions are reported in the study. In addition the Artificial Intelligence In Genomics study also shifts its attention with an in-depth competitive landscape, defined growth opportunities, market share coupled with product type and applications, key companies responsible for the production, and utilized strategies are also marked.

Key players in the global Artificial Intelligence In Genomics marketIBM Corporation (United States), Microsoft Corporation (United States), NVIDIA Corporation (United States), Deep Genomics (Canada), BenevolentAI (United Kingdom), Fabric Genomics Inc. (United States), Verge Genomics (United States), Cambridge Cancer Genomics (United Kingdom), Sophia Genetics (United States), Data4Cure Inc. (United States). Free Sample Report + All Related Graphs & Charts @: https://www.advancemarketanalytics.com/sample-report/173521-global-artificial-intelligence-in-genomics-market Although genomic medicine has achieved great advances in recent years, the clinical use of genomics is still evolving as new understanding and technology emerge. One key problem is making sense of exceptionally huge amounts of genomic sequence data and properly integrating and examining it with other relevant information, such as other molecular or clinical data. AI-based computer vision methods are set to change image-based diagnostics in clinical diagnostics, while other AI subtypes have begun to show comparable promise in diverse diagnostic modalities. Deep learning is a sort of AI technique that is used to handle vast and complicated genomic datasets in particular fields, such as clinical genomics.What's Trending in Market:

Rising Adoption of AI in Precision Medicine Segment

Challenges:

Data Theft or Leakage

High Initial Investment

Market Growth Drivers:

High Investments in AI for Genomics

Growth in Healthcare Infrastructure

The Artificial Intelligence In Genomics industry report further exhibits a pattern of analyzing previous data sources gathered from reliable sources and sets a precedent growth trajectory for the Artificial Intelligence In Genomics market. The report also focuses on a comprehensive market revenue streams along with growth patterns, Local reforms, COVID Impact analysis with focused approach on market trends, and the overall growth of the market.Moreover, the Artificial Intelligence In Genomics report describes the market division based on various parameters and attributes that are based on geographical distribution, product types, applications, etc. The market segmentation clarifies further regional distribution for the Artificial Intelligence In Genomics market, business trends, potential revenue sources, and upcoming market opportunities.

Download PDF Sample of Artificial Intelligence In Genomics Market report @ https://www.advancemarketanalytics.com/download-report/173521-global-artificial-intelligence-in-genomics-market The Global Artificial Intelligence In Genomics Market segments and Market Data Break Down are illuminated below: by Application (Diagnostics, Drug Discovery & Development, Precision Medicine, Agriculture & Animal Research, Other), Technology (Deep Learning, Reinforcement Learning, Supervised Learning, Unsupervised Learning, Others), End Use (Hospitals, Specialty Clinics), Functions (Genome Sequencing, Gene Editing, Clinical Workflows, Predictive Genetic Testing), Component (Software, Services (Managed, Professional)) The Artificial Intelligence In Genomics market study further highlights the segmentation of the Artificial Intelligence In Genomics industry on a global distribution. The report focuses on regions of LATAM, North America, Europe, Asia, and the Rest of the World in terms of developing market trends, preferred marketing channels, investment feasibility, long term investments, and business environmental analysis. The Artificial Intelligence In Genomics report also calls attention to investigate product capacity, product price, profit streams, supply to demand ratio, production and market growth rate, and a projected growth forecast.In addition, the Artificial Intelligence In Genomics market study also covers several factors such as market status, key market trends, growth forecast, and growth opportunities. Furthermore, we analyze the challenges faced by the Artificial Intelligence In Genomics market in terms of global and regional basis. The study also encompasses a number of opportunities and emerging trends which are considered by considering their impact on the global scale in acquiring a majority of the market share.The study encompasses a variety of analytical resources such as SWOT analysis and Porters Five Forces analysis coupled with primary and secondary research methodologies. It covers all the bases surrounding the Artificial Intelligence In Genomics industry as it explores the competitive nature of the market complete with a regional analysis.

Brief about Artificial Intelligence In Genomics Market Report with TOC @ https://www.advancemarketanalytics.com/reports/173521-global-artificial-intelligence-in-genomics-market Some Point of Table of Content:Chapter One: Report OverviewChapter Two: Global Market Growth TrendsChapter Three: Value Chain of Artificial Intelligence In Genomics MarketChapter Four: Players ProfilesChapter Five: Global Artificial Intelligence In Genomics Market Analysis by RegionsChapter Six: North America Artificial Intelligence In Genomics Market Analysis by CountriesChapter Seven: Europe Artificial Intelligence In Genomics Market Analysis by CountriesChapter Eight: Asia-Pacific Artificial Intelligence In Genomics Market Analysis by CountriesChapter Nine: Middle East and Africa Artificial Intelligence In Genomics Market Analysis by CountriesChapter Ten: South America Artificial Intelligence In Genomics Market Analysis by CountriesChapter Eleven: Global Artificial Intelligence In Genomics Market Segment by TypesChapter Twelve: Global Artificial Intelligence In Genomics Market Segment by Applications

Buy the Latest Detailed Report @ https://www.advancemarketanalytics.com/buy-now?format=1&report=173521 Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, West Europe or Southeast Asia.

Contact US : Craig Francis (PR & Marketing Manager) AMA Research & Media LLP Unit No. 429, Parsonage Road Edison, NJ New Jersey USA – 08837 Phone: +1 201 565 3262, +44 161 818 8166 sales@advancemarketanalytics.com Connect with us at https://www.linkedin.com/company/advance-market-analytics https://www.facebook.com/AMA-Research-Media-LLP-344722399585916 https://twitter.com/amareport

[versatile-blogger-1]

Global Spatial Genomics Transcriptomics Market Is Estimated To Witness High Growth Owing To Increasing Adoption of Spatial Genomics Technologies

Market Overview: Spatial genomics transcriptomics combines the technologies of spatial transcriptomics and genomics to analyze gene expression within the context of tissue architecture. This innovative approach allows researchers to study the spatial organization of gene expression within individual cells, leading to a better understanding of various biological processes and disease mechanisms. The market for spatial genomics transcriptomics is driven by the increasing adoption of these technologies in various research applications, including cancer research, neurobiology, developmental biology, and immunology. The ability to analyze gene expression within the context of tissue architecture provides valuable insights into cell-to-cell interactions, cellular heterogeneity, and spatial relationships, making it a powerful tool for biomedical research. The global Spatial Genomics Transcriptomics Market Size is estimated to be valued at US$ 262.7 million in 2023 and is expected to exhibit a CAGR of 13% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights. Market Key Trends: One key trend driving the growth of the spatial genomics transcriptomics market is the increasing demand for single-cell analysis. Single-cell analysis allows researchers to study individual cells rather than bulk population samples, providing a deeper understanding of cellular heterogeneity and development. Spatial genomics transcriptomics takes single-cell analysis a step further by incorporating spatial information, enabling researchers to study gene expression within the context of tissue architecture. This integrated approach allows for a more comprehensive analysis of complex biological systems and has the potential to revolutionize our understanding of cellular processes and disease mechanisms. For example, 10x Genomics, one of the key players in the spatial genomics transcriptomics market, offers the Visium Spatial Gene Expression Solution, which enables researchers to analyze gene expression in intact tissue sections. This technology allows for the identification of cell types, mapping of gene expression, and analysis of the spatial relationships between cells. By combining single-cell analysis with spatial information, researchers can gain valuable insights into the role of gene expression in tissue development and disease progression. PEST Analysis: Political: The spatial genomics transcriptomics market is influenced by government regulations and policies regarding genomics research and healthcare. Government funding and support for research initiatives can drive market growth. Economic: The market is driven by increasing investment in genomics research and the growing demand for personalized medicine. The economic factors, such as GDP growth, healthcare expenditure, and disposable income, also impact the adoption of spatial genomics transcriptomics technologies. Social: The growing prevalence of chronic diseases and the need for better diagnostic and treatment options are driving the demand for spatial genomics transcriptomics technologies. The increasing awareness and acceptance of personalized medicine among patients and healthcare professionals are also contributing to market growth. In conclusion, the spatial genomics transcriptomics market is poised for significant growth due to the increasing adoption of these technologies in various research applications. The integration of spatial information with gene expression data provides valuable insights into cellular processes and disease mechanisms, driving the demand for spatial genomics transcriptomics technologies. With advancements in genomics research and technological innovation, this market is set to revolutionize our understanding of biology and contribute to the development of personalized medicine.

[futuretonext]

The Global Genomic Data Analysis & Interpretation Market is likely to grow at a CAGR of around 11.10% during the forecast period, i.e., 2022-27, says MarkNtel Advisors. The market growth attributes principally to the burgeoning cancer cases worldwide, encouraging numerous biotechnology companies to develop genomic software solutions for data analysis to help clinicians provide precision oncology treatments.

[nuadox]

World’s largest epilepsy study reveals ‘genetic architecture’ and points to new therapies

- By Luciana Constantino , Agência FAPESP -

Considered the largest genetic study of epilepsy in the world, a study published in the journal Nature Genetics reveals specific alterations in DNA that signal a greater risk of the brain disorder.

Identifying these alterations will improve diagnosis and advance the possibility of new treatments for the disease.

The researchers identified 26 different areas (loci) of the genome that are linked to epilepsy, with 29 genes thought to play an important role in the disorder. Of these genes, 17 were associated with epilepsy for the first time; ten are linked to the development of the disease when mutated or altered (known as monogenic epilepsy genes) and the other seven are known to already have approved drugs that focus on treating autism spectrum disorders.

Analysis of the subtypes revealed significantly different “genetic architectures” mainly between two subtypes of epilepsy – focal and generalized – and common variations in DNA can explain between 39.6% and 90% of the genetic risk for the latter type.

Coordinated by a consortium of the International League Against Epilepsy (ILAE) involving more than 350 scientists, the study compared data from 29,944 people with the disease to those of 52,538 control subjects. It included epilepsy cases of European (92%), African (3%) and Asian (5%) descent.

Brazil was the only Latin American representative through the Brazilian Institute of Neuroscience and Neurotechnology (BRAINN), a FAPESP Research, Innovation and Dissemination Center (RIDC) based at the State University of Campinas (UNICAMP).

“We at BRAINN were involved in all stages of the work, from the detailed characterization of the patients from a clinical, imaging and neurophysiological point of view – which we’re very good at – to planning the analyses, suggesting how they could be carried out and then checking the results. We were also actively involved in writing the article, which was submitted to the journal over a year ago. Many international studies exclude patients from Brazil because we have such great genomic diversity. However this study did a meta-analysis, which allows us to combine populations with different genomic structures. For the future, we want to expand this diversity even more,” Iscia Teresinha Lopes-Cendes, a professor at UNICAMP’s School of Medical Sciences and co-author of the BRAINN article, told Agência FAPESP.

There are an estimated 2 million Brazilians with epilepsy, at least 25% of whom are uncontrolled, according to the Ministry of Health. Worldwide, the World Health Organization (WHO) estimates that 50 million people are affected by the disorder, a third of whom are resistant to the treatments available on the market.

A highly hereditary neurological disease with no cure, epilepsy causes seizures, up to 40 or 50 a day in the most severe cases, leading to loss of consciousness and falls. Uncontrolled seizures not only disrupt the patient’s daily routine but also pose a serious risk of sudden and premature death.

Treatment involves a combination of medications, which are not always effective. Most medications reduce the activity of neurons across the board, which controls seizures, but they have side effects. An alternative is surgery to remove the part of the brain affected by the malformation.

Now, the researchers are proposing some medications that are normally used for other conditions, but act on the epilepsy risk genes identified in the study.

Knowledge over time

Recognizing the complexity of the genetic and environmental factors related to epilepsy, the consortium was formed in 2010 to collaborate on investigating large datasets at an international level.

“This is an important milestone for the ILAE Consortium on Complex Epilepsies and shows what can be achieved when scientists collaborate openly and share data from around the world,” said the league’s president, Professor Helen Cross, in a press release.

To arrive at the results suggesting different genetic architectures between focal and generalized forms of epilepsy, genetic data were combined with databases of phenotypic information, expanding the sample to more than 51,600 patients and 1 million “controls.” This discovery of the different genetic framework for the different types of epilepsy provides clues to understanding the various syndromes.

In their work, the scientists point out that the proteins that carry electrical impulses through the gaps between the brain’s neurons are part of the risk for generalized forms of epilepsy. In this sense, they emphasize the importance of accurately characterizing or classifying specific epileptic syndromes (syndromic phenotyping) in order to better understand the genetic basis of the disease.

An advocate of studies with so-called “pure data,” Lopes-Cendes says that she is now working specifically on mesial temporal lobe epilepsy (MTLE) with hippocampal atrophy. “We’ve been continuously generating data for specific research on the topic. I’d argue that in certain studies, mixing information from different types of epilepsy can ’dilute’ the data and not highlight results that might appear if the group of patients studied was more homogeneous. I think a balance is needed,” she adds.

In early 2023, the researcher and her group published another article that deepened our understanding of MTLE, considered the most common and refractory to pharmacological treatment, by evaluating, for the first time, the profile of messenger RNA (mRNA, a molecule that contains the information for the production of proteins) from surgical tissue obtained from patients.

Because of her work in genetics, Lopes-Cendes was recently invited by the WHO to join the new Technical Advisory Group on Genomics (TAG-G), which is responsible for contributing to the process of accelerating access to genomic knowledge and technologies, especially in low- and middle-income countries. The group consists of 15 scientists from different countries.

The article “GWAS meta-analysis of over 29,000 people with epilepsy identifies 26 risk loci and subtype-specific genetic architecture” can be read at: www.nature.com/articles/s41588-023-01485-w.

This text was originally published by FAPESP Agency according to Creative Commons license CC-BY-NC-ND. Read the original here.

--

Read Also

For epilepsy sufferers, cutting-edge technology offers early alerts of seizures

[nerdybeardcollective]

Investment Surge in GLP-1 Drugs Market: Trends and Future Prospects

Market Growth and Investment Trends

The GLP-1 drugs market has seen substantial investment from pharmaceutical companies and venture capitalists. This is driven by the increasing prevalence of type 2 diabetes and obesity, coupled with the efficacy of GLP-1 drugs in managing these conditions. Key trends include:

Rising Prevalence of Diabetes and Obesity: The global rise in lifestyle-related health issues is fueling demand for effective treatments.

Innovative Drug Development: Companies are investing heavily in R&D to develop next-generation GLP-1 drugs with improved efficacy and fewer side effects.

Strategic Collaborations and Partnerships: Collaborations between pharmaceutical giants and biotech firms are accelerating innovation and market entry of new drugs.

Recent Developments

Several notable developments have occurred in the GLP-1 drugs market:

New Drug Approvals: Regulatory bodies like the FDA and EMA have recently approved several new GLP-1 receptor agonists, expanding treatment options.

Clinical Trials and Research: Ongoing clinical trials are investigating the broader therapeutic potential of GLP-1 drugs, including their effects on cardiovascular health and non-alcoholic fatty liver disease (NAFLD).

Technological Advancements: Innovations in drug delivery systems, such as oral formulations and long-acting injectables, are enhancing patient compliance and convenience.

Browse Press Release

Future Opportunities

The future of the GLP-1 drugs market holds numerous opportunities for growth and innovation:

Expansion into New Therapeutic Areas: Research suggests potential applications of GLP-1 drugs in conditions beyond diabetes and obesity, such as neurodegenerative diseases and inflammation.

Personalized Medicine: Advances in genomics and biomarkers may enable personalized GLP-1 therapies tailored to individual patient profiles, improving outcomes.

Emerging Markets: Increasing healthcare access and rising diabetes prevalence in emerging markets present significant growth opportunities for GLP-1 drugs.

Conclusion

The GLP-1 drugs market is poised for remarkable growth, driven by robust investment, innovative developments, and expanding therapeutic applications. As research progresses and new technologies emerge, GLP-1 receptor agonists will play a crucial role in addressing the global burden of diabetes, obesity, and potentially other diseases, offering improved health outcomes for millions.

About iDataAcumen

iDataAcumen is a global business intelligence and management consulting firm providing data driven solutions to a wide array of business challenges. Our clients are present across major geographies globally and belong to industries ranging mainly from healthcare, pharmaceuticals, life science, biotechnology, medical devices, food industry, chemicals, among others. We have catered to more than 500 clients across these industries.

We aspire to help our clients build a sustainable business by providing them robust business insights that are derived from sound data driven analysis. In today’s ever changing business environment, its become important to look objectively at your own business just as it is important to look at the competition. Technological advancement including but not limited to big data, artificial intelligence, and machine learning are helping industries worldwide to make informed business decisions. Our research process also makes use of some of these advanced tools to uncover valuable insights from vast amount of data to arrive at logical conclusions.

[trendingreportz]

Genomics Market - Forecast(2024 - 2030)

Global Genomic Market Overview:

A genome is the genetic material of an organism. It includes both the genes and the noncoding DNA, as well as mitochondrial DNA and chloroplast DNA. The study of genomes is called genomics. The genomics market is gaining traction owing to its applications in various fields of study such as intragenomic phenomenon including epistasis, pleiotropy, heterosis, and other interactions between loci and alleles within the genome. In this era of medical and life science innovations shaping itself as an inevitable uptake for sustainability of mankind, the genomic research is poised for exponential growth owing to imperative genetic innovations feeding off it. Abundant potential has driven this arcade to reach a staggering market size of $16 billion - $16.5 billion as of 2018, and the demand is estimated to increment at formidable CAGR of 9.2% to 10.2% during the forecast period of 2019 to 2025.

Request Sample

Global Genomic Market Outlook:

Genomics is extensively employed in healthcare, agriculture, biotechnology, DNA sequencing, and diagnostics. In the healthcare segment, genomics is used for the development of vaccines and drugs. This segment leads the application vertical and is growing with a CAGR of 10.1%-10.7 % through to 2025. Genomics plays a significant part in diagnosis of several genetic disorders. It has an ample scope in personalized medication as it can advocate a medical management constructed on the genetic face of a person with the help of clinical data and AI.  It is also applied in synthetic biology and bioengineering. Genomics research in agriculture is hired for plant breeding and genetics to cultivate crop production. The understanding of gene function and the accessibility of genomic maps along with an enhanced understanding of genetic variant will aid the plant breeders to identify the traits and then manipulate those traits to obtain a high yield. All these factors affecting the enormous medical and agricultural sector are all set to stroke the genomics market with abundant demand.

Inquiry Before Buying

Global Genomic Market Growth Drivers:

As per the National Center for Biotechnology Information, U.S, the progression in oncology (study and treatment of tumor) expenses is forecast to rise 7%–10% annually throughout 2020, with universal oncology cost exceeding $150 billion[1]. As per the WHO, cancer is a leading cause of death worldwide, accounting for an estimated 9.6 million deaths in 2018[2]. And the total annual economic cost of cancer at the initial period of this decade was estimated at approximately $1.16 trillion. Thus the application of genomics in exploring cell-free circulating DNA by several R&D sectors as a potential biomarker for cancers is driving the market towards exponential growth. The genomics market with its current potential displays all the necessary traits it can adapt in the coming years to divert a huge chunk of traffic and revenue from the omnipresent cancer diagnostics.

As per the Food and Agriculture Organization of United Nations, between 1960 and 1990 the arable land increased by 1.5 billion ha, and in the recent past decades the elevation recorded is just 155 million ha[3]. With decreasing arable floor and the increasing global population augmenting the demand for food by 70% (by 2050), obtaining a high yield is a major trend in the agricultural sector. Genomics market is all set to capitalize on this unprecedented demand scenario. Genomics supplements the understanding of gene function and the accessibility of genomic maps along with an enhanced understanding of genetic variant, thus aiding the plant breeders to identify the traits and then manipulate those traits to obtain a high yield.

After an acute analysis of the regional insights of the global genomics market, North America is revealed to hold 39% to 40% of the entire global market size as of 2018. Such dominance can be attributed to several aspects such as cumulative investment on research by federal administrations, growing patient awareness, and accessibility of urbane healthcare facilities.

Schedule a Call

Global Genomics Market Players Perspective:

Some of other key players profiled in this IndustryARC business intelligence report are Beckton Dickson, Synthetic Genomics Inc. (SGI) ,Cepheid, Inc., Affymetrix, Inc., Bio-Rad Laboratories, Inc., Agilent Technologies, GE Healthcare, Illumina, Inc., Danaher Corporation,F. Hoffmann-La Roche, QIAGEN, Thermo Fisher Scientific and PacBio (Pacific Biosciences of California). Majority of the companies mentioned are situated in North America augmenting the regional affluence in the global market.

Global Genomics Market Trends:

High overload owing to a wide range of reagents and consumables has propelled companies into approving different policies to endure in the market and stay ahead of the curve.

For instance, in January 2017, BD launched Precise WTA Reagents for precise and guileless quantification of hereditary data form single cell analysis. Moreover, in July 2016, SGI-DNA entered into a distribution agreement with VWR International, an American company involved in the distribution of research laboratory products, with over 1,200,000 items to more than 250,000 customers in North America and Europe.

Genomics Market Research Scope

The base year of the study is 2018, with forecast done up to 2025. The study presents a thorough analysis of the competitive landscape, taking into account the market shares of the leading companies. It also provides information on unit shipments. These provide the key market participants with the necessary business intelligence and help them understand the future of the Genomics Market. The assessment includes the forecast, an overview of the competitive structure, the market shares of the competitors, as well as the market trends, market demands, market drivers, market challenges, and product analysis. The market drivers and restraints have been assessed to fathom their impact over the forecast period. This report further identifies the key opportunities for growth while also detailing the key challenges and possible threats. The key areas of focus include the types of equipment in the Genomics Market, and their specific applications in different phases of industrial operations.

Buy Now

Genomics Market Report: Industry Coverage

Types of Solutions Genomics Market:

By Product Types- Microarray chip, Sequencers.

By Application- Genotyping, SNP analysis.

By End-User- Anthropology, Diagnostics.

The Genomics Market report also analyzes the major geographic regions for the market as well as the major countries for the market in these regions. The regions and countries covered in the study include:

North America: The U.S., Canada, Mexico

South America: Brazil, Venezuela, Argentina, Ecuador, Peru, Colombia, Costa Rica

Europe: The U.K., Germany, Italy, France, The Netherlands, Belgium, Spain, Denmark

APAC: China, Japan, Australia, South Korea, India, Taiwan, Malaysia, Hong Kong

Middle East and Africa: Israel, South Africa, Saudi Arabia

[emanuel0602]

How Artificial Intelligence can both benefit us and affect humans?

The evolution of artificial intelligence (AI) brings both significant benefits and notable challenges to society.

And my opinion about artificial intelligence is that can benefit us but in a certain way it can also affect us.

And you will say why I think that is good because mainly it is because several aspects are going to change and for some things the help you give us will be useful but for other things it is going to screw us up very well.

And now I'm going to tell you some Advantages and some Disadvantages of AI

Benefits:

1. Automation and Efficiency: AI automates repetitive tasks, increasing productivity and freeing humans to focus on more complex and creative work. This is evident in manufacturing, customer service, and data analysis.

2. Healthcare Improvements: AI enhances diagnostics, personalizes treatment plans, and aids in drug discovery. For example, AI algorithms can detect diseases like cancer from medical images with high accuracy.

3. Enhanced Decision Making: AI systems analyze large datasets to provide insights and predictions, supporting better decision-making in sectors such as finance, marketing, and logistics.

4. Personalization: AI personalizes user experiences in areas like online shopping, streaming services, and digital advertising, improving customer satisfaction and engagement.

5. Scientific Research: AI accelerates research and development by identifying patterns and making predictions that can lead to new discoveries in fields like genomics, climate science, and physics.

Challenges:

1. Job Displacement: Automation can lead to job loss in sectors where AI can perform tasks traditionally done by humans, leading to economic and social challenges.

2. Bias and Fairness: AI systems can perpetuate and amplify existing biases if they are trained on biased data, leading to unfair outcomes in areas like hiring, law enforcement, and lending.

3. Privacy Concerns: The use of AI in data collection and analysis raises significant privacy issues, as vast amounts of personal information can be gathered and potentially misused.

4. Security Risks: AI can be used maliciously, for instance, in creating deepfakes or automating cyberattacks, posing new security threats that are difficult to combat.

5. Ethical Dilemmas: The deployment of AI in critical areas like autonomous vehicles and military applications raises ethical questions about accountability and the potential for unintended consequences.

Overall, while the evolution of AI offers numerous advantages that can enhance our lives and drive progress, it also requires careful consideration and management of its potential risks and ethical implications. Society must navigate these complexities to ensure AI development benefits humanity as a whole.

[sarasa-cat]

YES! Gattaca tops the list! *fist pump*

I'll explain that one:

Gattaca takes place in a near-future version of our world in which genomic analysis of sperm and eggs is regularly used for eugenic selection when people plan a pregnancy. No one --- or, at least, no one respectable --- has children "the natural way" any more. A person's genetic code determines all major aspects of their life and discrimination based on genetic flaws is baked into every aspect of society.

Your genes are your destiny, regardless of probabilities and environmental interactions. In this dystopian society, any such risk must be avoided. Thus, if you possess genes that indicate a likelihood of certain diseases or conditions, your opportunities are limited. Corporations engage in genetic testing as a condition of employment. Single people in the dating scene secretly test potential partner's code to make sure they are getting involved with someone who has excellent genes. Thus, genetic code enforces economic class structure.

The movie's story centers around the fate of two men: The main character is Vincent Freeman (played by Ethan Hawke) who was naturally conceived and has a genetic profile that rates him as having a high probability of severe health disorders and an exceedingly short lifespan. Growing up as a victim of low expectations, Vincent is stuck in working as a janitor at an areospace corporation -- a field that Vincent is deeply interested in.

The other central character is Jerome Eugene Morrow (played by Jude Law) who is deemed genetically perfect but fate left him with a severe handicap and a hell of a lot of cynicism and depression.

Jerome's genetic code is worth a lot of money on the black market, which is how Vincent and Jerome meet.

.

Gattaca came out in 1997, which is also key. At that time the Human Genome Project was seven years into its way of mapping and sequencing every gene in human beings. (The Genome Project completed in 2003).

Also, at that time, the field of bioethics was loudly raising the alarm on what would happen when companies, governments, or both, have unprecedented access to every person's genetic code.

This film was so accurate in portraying our potential future that many molecular biologists praised the film or, at least, highly recommended the film to their molbio colleagues such that other geneticists could "understand the perception of our trade held by so many of the public-at-large" (quote from Lee Silver, MolBio at Princeton, who at least then, was exceedingly pro-designer baby. Silver now runs a genetic screening company).

In addition to being nominated for and winning a number of film awards, the movie is visually beautiful and the performances by Jude Law & Ethan Hawke are stellar. The tension is palpable.

Also, since this is tumblr, I should also mention that the fanfic potential in this film is *chefs kiss*.

Highly recommended.

[industrynewsupdates]

Automated Liquid Handling Technologies Market: Key Trends and Growth Opportunities

The global automated liquid handling technologies market size was estimated at USD 4.20 billion in 2030 and is anticipated to grow at a compound annual growth rate (CAGR) of 10.5% from 2024 to 2030. Automated liquid handling technology has changed wet lab research handling by allowing substantial restructuring of the manufacturing and research facilities of the pharma and biotech companies. There is increasing acceptance of liquid handling robots to restore the conventionally reserved wet lab bench work areas. This factor is expected to drive the market.

The key aspects of maintaining the overall productivity of these companies are the efficient and accurate handling of the liquid samples. This makes biopharma companies and research laboratories rely greatly on robotics and automation. Usage of preprogrammed and customizable procedures reduces the need for management as it allows scientists to invest additional time in the analysis of data. Moreover, the buyers have a choice to select from various liquid handling technologies such as positive displacement, air displacement dispensing, acoustic, and piezoelectric. This choice to pick from a variety of automated liquid handlers impacts the power of the buyer. Significant market players are involved in manufacturing low-volume liquid handling systems owing to the increasing adoption of microplates and microfluidics in lab processing.

The COVID-19 pandemic has augmented the industry growth significantly as the demand for ALHsystem has increased with an upsurge in the need to process the specimens quicker in the laboratory for COVID-19 virus research with the examination of virus genetic makeup and study of COVID-19 virus genetic mutations. Thus, the pandemic has positively impacted the market. Moreover, new product launches accelerated the growth of the market during the pandemic. For instance, in April 2022, Novacyt introduced a novel ALH system to meet the increasing requirement for no manual pipetting in COVID-19 Polymerase Chain Reaction testing. Furthermore, in March 2020, Hamilton Company announced numerous automation-related initiatives to help healthcare researchers and workers during the coronavirus pandemic. The company launched two innovative automated assay-ready workstations, established on the company’s liquid handling workstation (Microlab STARlet), which enables rapid, research-based testing of SARS-CoV-2 and high-throughput diagnostic.

Gather more insights about the market drivers, restrains and growth of the Automated Liquid Handling Technologies Market

Automated Liquid Handling Technologies Market Report Highlights

• By product, the automated liquid handling workstations segment held the largest share in 2022. The growing competition among the pharmaceutical companies and their pursuit of new drugs to treat diseases effectively drive the adoption of automated workstations

• Multipurpose workstations are projected to witness the fastest growth during the forecast period due to their rapid adoption by the pharma and biopharma CROs. These workstations enable microplate washing, multichannel pipetting, and bulk reagent dispensing within a single unit

• By application, the drug discovery and ADME-Tox research segment dominated the market in 2022. Various applications in drug discovery and ADME Tox include stepwise serial dilution over a wide concentration range, selection and transfer of compounds for the retest, and confirmatory and further analysis

• Cancer and genomic research is expected to witness the fastest growth during the forecast period owing to the ability of these workstations to handle multiple samples of microliter to picoliter volume

• Workflow complexity and the need for the fastest target screening resulted in the increase in the installation of automated workstations by the pharmaceutical and biotechnology companies

• North America dominated the market in 2022 owing to the rapid adoption of advanced platforms, the high cost of hiring skilled professionals, and the presence of key players

• Asia Pacific is expected to expand at the fastest CAGR during the forecast period owing to the rapid progress of the pharma and biopharmaceutical companies in the region

• High economic developments in APAC countries are anticipated to increase investments in the life science, medicine, and pharmaceutical sectors. Progress in these sectors is expected to fuel the demand for automated workstations, especially those based on microfluidics

Automated Liquid Handling Technologies Market Segmentation

Grand View Research has segmented the global automated liquid handling technologies market report based on product, application, end-user, and region:

Automated Liquid Handling Technologies Product Outlook (Revenue, USD Million, 2018 - 2030)

• Automated Liquid Handling Workstations

o By Assembly

o By Type

• Reagents & Consumables

o Reagents

o Accessories

Automated Liquid Handling Technologies Application Outlook (Revenue, USD Million, 2018 - 2030)

• Drug Discovery & ADME-Tox Research

• Cancer & Genomic Research

• Bioprocessing/Biotechnology

• Others

Automated Liquid Handling Technologies End-User Outlook (Revenue, USD Million, 2018 - 2030)

• Academic & Research Institutes

• Pharmaceutical & Biotechnology Companies

• Contract Research Organizations

Automated Liquid Handling Technologies Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o U.K.

o Germany

o France

o Italy

o Spain

o Denmark

o Sweden

o Norway

• Asia Pacific

o Japan

o China

o India

o South Korea

o Australia

o Thailand

• Latin America

o Brazil

o Mexico

o Argentina

• Middle East & Africa

o South Africa

o Saudi Arabia

o UAE

o Kuwait

Order a free sample PDF of the Automated Liquid Handling Technologies Market Intelligence Study, published by Grand View Research.

[versatile-blogger-1]

Genomics Market Expected To Witness High Growth Driven By Advancements In Technology And Rising Demand For Personalized Medicine

A) Market Overview:

Genomics is the study of genes and their functions, with a focus on understanding the structure, function, evolution, mapping, and editing of genomes. It plays a crucial role in personalized medicine, drug discovery, and the development of precision therapies. The market mainly consists of products such as instruments & consumables, services, and software used in genomic research and diagnostics.

The global Genomics Market is estimated to be valued at US$ 46.2 Bn in 2023 and is expected to exhibit a CAGR of 12.4% over the forecast period 2023-2028, as highlighted in a new report published by Coherent Market Insights.

B) Market Dynamics:

The global Genomics Market is driven by two major factors. Firstly, advancements in technology have revolutionized genomics research and diagnostics. The development of Next-Generation Sequencing (NGS) technologies and its applications in various genomic studies have significantly contributed to market growth. NGS enables faster and cost-effective sequencing of DNA, RNA, and proteins, thereby facilitating a deeper understanding of diseases at a molecular level.

Secondly, there is a rising demand for personalized medicine, which utilizes genomic information to tailor medical treatments to individual patients. The increasing prevalence of chronic diseases such as cancer and genetic disorders has created a need for more targeted therapies. Genomic testing enables the identification of specific genetic mutations associated with these diseases, allowing for personalized treatment plans.

C) Market Key Trends:

One key trend observed in the Genomics Market is the growing adoption of direct-to-consumer genetic testing. Companies such as 23andMe provide consumers with the opportunity to access their genetic information through at-home testing kits. This trend has gained popularity due to increased consumer awareness and curiosity about their DNA and ancestry.

For example, 23andMe offers ancestry reports, health predisposition reports, and carrier status reports, providing individuals with insights into their genetic background and potential health risks. This trend is expected to continue, as more people are interested in exploring their genetic information for various purposes.

D) SWOT Analysis:

Strength:

1. Advancements in technology - Continued advancements in genomic technologies such as NGS drive the market's growth.

2. Increasing demand for personalized medicine - The rising prevalence of chronic diseases and genetic disorders fuels the adoption of genomic approaches in clinical decision-making.

Weakness:

1. High costs associated with genomic testing - The cost of genomic tests and sequencing technologies may limit their accessibility, hindering market growth.

2. Regulatory challenges - Stringent regulations regarding the use and sharing of genetic data pose challenges for the market expansion.

Opportunity:

1. Growing applications in non-invasive prenatal testing - Genomics has the potential to revolutionize prenatal care by enabling non-invasive detection of fetal genetic abnormalities.

2. Expanding use of genomics in agriculture - The agricultural sector can benefit from genomics-based technologies for crop improvement and disease resistance.

Threats:

1. Ethical and privacy concerns - The collection and utilization of genetic data raise ethical questions and privacy concerns among individuals and regulatory bodies.

2. Lack of awareness and limited infrastructure - Limited awareness about genomics and inadequate infrastructure in certain regions can hinder market growth.

E) Key Takeaways:

- The global genomics market is expected to witness high growth, exhibiting a CAGR of 12.4% over the forecast period, driven by advancements in technology and rising demand for personalized medicine.

- North America is currently the largest market for genomics, owing to the presence of well-established healthcare infrastructure, increased funding for genomics research, and a growing consumer base for direct-to-consumer genetic testing.

- Key players operating in the global genomics market include Thermo Fisher Scientific, Agilent Technologies, Bio-Rad Laboratories, Illumina, Pacific Biosciences, Oxford Nanopore Technologies, 23andMe, Foundation Medicine, Hoffmann-La Roche Ltd., and Myriad Genetics Inc. These players focus on product development, partnerships, and acquisitions to maintain their market position and enhance their product offerings.

[mordorintelligencemarketresearch]

Human Microbiome Market is anticipated to grow to USD 2.24 billion by 2030

Market Overview

The Human Microbiome Market is projected to be valued at USD 1.05 billion in 2025 and is anticipated to grow to USD 2.24 billion by 2030, reflecting a compound annual growth rate (CAGR) of 16.37% during the forecast period from 2025 to 2030. This impressive growth is driven by the increasing recognition of the microbiome's importance in health and disease, advancements in microbiome research, and the expanding pipeline of microbiome-based products, including probiotics and microbiome-based therapeutics.

The human microbiome market is multidisciplinary, involving a wide array of scientific fields such as genomics, microbiology, immunology, and biotechnology. As our understanding of the microbiome's functions and its impact on disease deepens, the potential for microbiome-based therapies and diagnostics expands, offering new opportunities for companies operating in this space.

Key Drivers of Market Growth

Rising Awareness of the Microbiome's Role in Health Over the past decade, research has shown that the human microbiome is essential for maintaining health. It plays a significant role in various biological processes, such as digestion, metabolism, immunity, and even brain function. The growing body of evidence linking imbalances in the microbiome to conditions such as obesity, diabetes, irritable bowel syndrome (IBS), cardiovascular disease, autoimmune disorders, and neurological conditions has fueled interest in the microbiome's potential for therapeutic interventions. As awareness of the microbiome's importance continues to rise, there is increasing demand for microbiome-based products, including probiotics, diagnostics, and treatments.

Advancements in Genomic and Metagenomic Technologies The rapid advancement of genomic and metagenomic technologies, such as next-generation sequencing (NGS), has revolutionized our ability to study the human microbiome. These technologies allow researchers to analyze the composition and function of the microbiome in unprecedented detail, providing valuable insights into how microbiota influence health and disease. The falling costs of sequencing and improved data analysis techniques have made it easier for scientists to explore the microbiome, opening up new opportunities for developing microbiome-based products and therapies.

Growth of Personalized Medicine Personalized medicine is transforming healthcare by tailoring treatments to individual patients based on their genetic and molecular profiles. The microbiome is a critical component of this shift toward personalized healthcare, as an individual's microbiome can influence their response to treatments, including drugs, diet, and lifestyle changes. As the understanding of the microbiome’s role in disease pathogenesis advances, microbiome-based diagnostics and therapeutics are becoming integral parts of personalized medicine. The growing focus on personalized medicine is expected to drive the demand for microbiome-based products that are tailored to an individual's microbiome composition.

Rising Demand for Probiotics Probiotics, live microorganisms that provide health benefits when consumed in adequate amounts, are one of the most widely recognized applications of microbiome science. The global probiotic market is expanding rapidly, with probiotics being used to address a wide range of health issues, including digestive disorders, immunity support, and mental health. Probiotics are also being increasingly incorporated into functional foods and beverages, as well as dietary supplements, contributing to the growth of the human microbiome market.

Growing Focus on Gut Health The gut microbiome, in particular, has been a primary focus of research due to its profound impact on digestion, metabolism, and immune function. A growing body of evidence has linked an imbalanced gut microbiome (dysbiosis) to a variety of conditions, including obesity, diabetes, inflammatory bowel disease (IBD), and even mood disorders such as anxiety and depression. This has led to a surge in demand for microbiome-based interventions, such as prebiotics, probiotics, and microbiome-based therapeutics aimed at restoring gut health. Additionally, the increasing popularity of gut-friendly diets, such as plant-based and fermented foods, is contributing to market growth.

Rising Investment in Microbiome Research and Development Government agencies, academic institutions, and private companies are investing heavily in microbiome research and development. These investments are supporting the discovery of new biomarkers, the development of microbiome-based diagnostics, and the creation of novel therapeutics targeting the microbiome. As a result, a growing number of startups and established companies are entering the microbiome space, bringing innovative products to market and contributing to the overall growth of the industry.

Market Segmentation

The human microbiome market can be segmented based on product type, application, and region:

By Product Type:

Probiotics: Probiotics are one of the most well-known and widely used products in the human microbiome market. They are primarily used to improve gut health, support digestion, and strengthen the immune system. Probiotics are available in various forms, including dietary supplements, functional foods, and beverages.

Microbiome-based Therapeutics: This category includes therapies that aim to manipulate the microbiome to treat specific health conditions. These therapeutics may include fecal microbiota transplants (FMT), bacteriophage therapy, and microbiome-modulating drugs.

Microbiome Diagnostics: Microbiome diagnostics use genomic, metagenomic, and other analytical techniques to assess the composition and diversity of the microbiome. These diagnostic tools help identify imbalances in the microbiome that may be contributing to health problems and can be used to guide personalized treatment options.

Prebiotics: Prebiotics are non-digestible food ingredients that promote the growth of beneficial bacteria in the gut. Prebiotics are increasingly being incorporated into functional foods and supplements to support microbiome health.

By Application:

Gut Health: The largest application segment, focused on improving digestive health and addressing conditions such as irritable bowel syndrome (IBS), Crohn's disease, and ulcerative colitis.

Immune System Support: The microbiome plays a key role in regulating immune function, and microbiome-based products are being used to support overall immunity and prevent infections.

Metabolic Disorders: The microbiome is linked to metabolic health, including conditions such as obesity, diabetes, and cardiovascular disease. Microbiome-based products are being developed to help manage or prevent these diseases.

Mental Health: Emerging research has shown that the gut microbiome has a strong influence on brain health, with imbalances in the microbiome being linked to conditions such as anxiety, depression, and autism. This area of research is gaining traction, and microbiome-based therapeutics for mental health are being developed.

Skin Health: The skin microbiome is also a growing area of research, with products being developed to address conditions such as acne, eczema, and psoriasis by restoring balance to the skin microbiome.

By Region:

North America: North America dominates the human microbiome market due to high levels of investment in research, a strong healthcare infrastructure, and growing consumer interest in probiotics and other microbiome-based products.

Europe: Europe is a significant market for microbiome-based products, driven by a rising focus on gut health, increasing consumer demand for probiotics, and advancements in microbiome research.

Asia Pacific: The Asia Pacific region is expected to experience rapid growth in the microbiome market, due to increasing awareness of the microbiome's importance, growing health consciousness, and rising demand for probiotics and personalized healthcare.

Latin America and Middle East & Africa: These regions are gradually adopting microbiome-based products, with rising healthcare awareness and expanding research initiatives contributing to market growth.

Challenges Facing the Market

Despite the rapid growth and potential of the human microbiome market, several challenges exist:

Scientific Complexity: The human microbiome is highly complex and dynamic, making it difficult to fully understand its functions and interactions. This scientific complexity poses challenges in developing effective microbiome-based treatments and diagnostic tools.

Regulatory Barriers: The regulatory framework for microbiome-based products is still evolving. Regulatory agencies must develop clear guidelines for the approval of microbiome-based therapeutics, diagnostics, and probiotics, which could slow down the development and commercialization of new products.

Ethical and Safety Concerns: The manipulation of the microbiome, particularly through interventions such as fecal microbiota transplants and genetically engineered probiotics, raises ethical and safety concerns. Ensuring that these products are safe and effective for human use is critical to gaining consumer trust and acceptance.

Future Outlook

The human microbiome market is set to experience explosive growth, driven by ongoing advancements in research, increased consumer demand for microbiome-based products, and the expanding applications of microbiome science in healthcare. As scientists continue to uncover the intricacies of the microbiome and its impact on human health, new therapeutic interventions and diagnostic tools will emerge, providing new opportunities for companies operating in this space.

Personalized microbiome treatments, improved probiotic products, and microbiome-based therapeutics for conditions ranging from digestive issues to mental health will likely be at the forefront of the market's growth. The development of microbiome-based drugs and treatments that target specific diseases will be key to revolutionizing healthcare and improving patient outcomes.

Conclusion

The human microbiome market is poised for rapid expansion, driven by breakthroughs in research and a growing understanding of the microbiome's critical role in health and disease. With applications spanning from gut health and immunity to mental health and personalized medicine, the human microbiome industry offers vast potential for innovation and growth. As the market evolves, it will unlock new opportunities to improve human health through microbiome-based solutions, transforming the future of healthcare.

For a detailed overview and more insights, you can refer to the full market research report by Mordor Intelligence

[globalinsightblog]

"Genetic Mutation Analysis: Unlocking the Secrets of DNA 🧬, $11.3 Billion Market by 2034"

Genetic Mutation Analysis Market is dedicated to identifying and characterizing genetic alterations, offering insights into disease mechanisms, diagnosis, and treatment strategies. Utilizing advanced technologies such as Next-Generation Sequencing (NGS), PCR, and microarrays, this market plays a pivotal role in sectors like healthcare, pharmaceuticals, and research, driving innovations in personalized medicine and genomics.

To Request Sample Report: https://www.globalinsightservices.com/request-sample/?id=GIS10968 &utm_source=SnehaPatil&utm_medium=Article

The market is witnessing robust growth, fueled by the rise of genomics and precision medicine. Oncology leads the market, spurred by the growing prevalence of cancer and the increasing need for targeted therapies. Following closely is the infectious diseases segment, driven by research into viral mutations and the global focus on pandemic preparedness. Regionally, North America dominates the market, supported by strong investments in biotechnology and a well-established healthcare infrastructure. Europe is the second-highest performing region, benefiting from governmental support for genomic research. The United States stands at the forefront, with its advanced technological capabilities and significant research funding. Meanwhile, China is rapidly emerging, bolstered by government initiatives and growing investments in healthcare.

Market Segmentation:

Type: SNP Analysis, CNV Analysis, Large-Scale Mutation Analysis

Technology: Next-Generation Sequencing, PCR, Microarray, Sanger Sequencing, CRISPR

Application: Oncology, Infectious Diseases, Neurological Disorders, Pharmacogenomics

End User: Hospitals, Research Institutes, Pharmaceutical Companies, Diagnostic Labs

In 2023, the market reached 300 million analyses globally, with NGS dominating, capturing 45% of the market share. This growth is attributed to NGS’s cost-effectiveness and high throughput, revolutionizing diagnostics and genetic research.

Key players like Illumina, Thermo Fisher Scientific, and Qiagen are leading market innovations. With projections indicating a 15% CAGR through 2033, the future of genetic mutation analysis is bright, driven by the integration of AI and machine learning for enhanced diagnostic accuracy.

#GeneticMutationAnalysis #Genomics #PersonalizedMedicine #NGS #PCR #Microarrays #CancerTherapies #TargetedTreatments #GeneticResearch #GeneticTesting #HealthcareInnovation #OncologyResearch #InfectiousDiseases #Pharmacogenomics #DataAnalysis #CloudBased #GeneticDiagnostics #AIInHealthcare #PrecisionMedicine #Biotechnology